David Lott, DO
Internal Medicine · Meridian, MSNPI 1558859884
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,200 of the $14,623 with a category attached, or 69.8%. Amgen accounts for 75.6% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $11,493, more than ten times the $14 reported in 2019. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $72.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- Abbott$507
- Bayer$408
- Novo Nordisk$395
- Lilly USA, LLC$379
- Corcept Therapeutics$369
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$10,20070%
- Food & beverage$4,40330%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $11,051 |
| Abbott | 21 | $507 |
| Bayer | 12 | $408 |
| Novo Nordisk | 24 | $395 |
| Lilly USA, LLC | 24 | $379 |
| Corcept Therapeutics | 20 | $369 |
| Tandem Diabetes Care, Inc. | 10 | $206 |
| Boehringer Ingelheim | 10 | $192 |
| Inspire Medical Systems, Inc. | 1 | $132 |
| Averitas Pharma Inc. | 5 | $116 |
| Insulet Corporation | 4 | $97 |
| Dexcom, Inc. | 4 | $94 |
| Pfizer | 4 | $72 |
| Medtronic | 3 | $71 |
| AstraZeneca(2 entities) | 4 | $66 |
| Antares Pharma, Inc. | 2 | $52 |
| AbbVie | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Sequel Med Tech, LLC | 2 | $45 |
| Enterra Medical, Inc. | 1 | $37 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Merck | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Novartis | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| BETA Bionics, Inc. | 2 | $19 |
| Nevro Corp. | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$10,450
- Inspire$132
- Kerendia$125
- FREESTYLE LIBRE 3$105
How this compares
$14,623 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 486 | $460,304 |
| OzempicSemaglutide | 330 | $307,075 |
| MounjaroTirzepatide | 170 | $182,161 |
| JardianceEmpagliflozin | 267 | $180,131 |
| Tresiba Flextouch U-100Insulin Degludec | 256 | $118,216 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 76 | $113,077 |
| Tresiba Flextouch U-200Insulin Degludec | 125 | $83,660 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 111 | $66,959 |
| FarxigaDapagliflozin Propanediol | 79 | $51,480 |
| Novolog FlexpenInsulin Aspart | 257 | $42,233 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $24,002 |
| TradjentaLinagliptin | 37 | $23,533 |
| JanuviaSitagliptin Phosphate | 35 | $22,996 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $18,714 |
| Humalog Kwikpen U-100Insulin Lispro | 69 | $15,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $379 | $646,817667 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $395 | $317,893356 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $192 | $209,245316 claims |
| AstraZenecaFarxiga | $66 | $51,48079 claims |
| MerckJanuvia | $33 | $22,99635 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $2,122264 claims |
| AbbVieSynthroid | $51 | $2,08938 claims |
| IBSA Pharma Inc.Tirosint-Sol | $15 | $1,38311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Meridian
- Muzaffar RahatMeridian$7K
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
- Charles HillOxford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.